Desuden fastslog CHMP, at der bør tilføjes information med hensyn til dosis- respons i afsnit 5. 1 (Farmakodynamiske egenskaber) i produktresumeet.
In addition, the CHMP agreed that information with regards to the dose response studies should be included in section 5.1 (Pharmacodynamic Properties) of the SPC.